Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 3, 2011, Pages

  Becker, Luis E ^a,b   Koleganova, Nadezda ^a   Piecha, Grzegorz ^a,c   Noronha, Irene L ^b   Zeier, Martin ^a   Geldyyev, Aman ^a   Kökeny, Gabor ^a   Ritz, Eberhard ^a   Gross, Marie Luise ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

ApoE ; Atherosclerosis; Uninephrectomy; Vascular calcification; Vitamin D analogs and derivates

Indexed keywords

APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN 2; CALCITRIOL; CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; PARICALCITOL; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; IMMUNOHISTOCHEMISTRY; INTIMA; KNOCKOUT MOUSE; MALE; MORPHOMETRICS; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 79954467253     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00042.2010     Document Type: Article

References (35)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction, and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
2. Berlyne GM, Mallick NP. Arterial calcification after vitamin D. Lancet 1:416, 1969.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617, 1998.
4. Bradford MM. A rapid, and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
5. Bro S, Bentzon JF, Falk E, Andersen CB, Olgaard K, Nielsen LB. Chronic renal failure accelerates atherogenesis in apolipoprotein E-defi-cient mice. J Am Soc Nephrol 14: 2466-2474, 2003.
6. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K. The apolipoprotein, and knockout mouse: the model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14: 311-316, 2003.
7. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22: 860-866, 2007.
8. Contiguglia SR, Alfrey AC, Miller NL, Runnells DE, Le Geros RZ. Nature of soft tissue calcification in uremia. Kidney Int 4: 229-235, 1973.
9. Drueke TB, McCarron DA. Paricalcitol the compared with calcitriol in patients undergoing hemodialysis. N Engl J Med 349: 496-499, 2003.
10. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 6: 93-107, 2008.
11. Farzaneh-Far A, Weissberg PL, Proudfoot D, Shanahan CM. Transcriptional regulation of matrix gla protein. Z Kardio 3: 38-42, 2001.
12. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, Robbins JA, Gardin JM. Risk factor for 5-year mortality in older adults: The Cardiovascular Health Study. JAMA 279: 585-592, 1998.
13. Ganesh SK, Stack AG, Levin NW, Hulbert-Sharon T, Port FK. Association of elevated serum PO4, Ca X PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
14. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification, and inorganic phosphate. Am J Kidney Dis 38: S34-S37, 2001.
15. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease, and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
16. Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, Berger I, Adamczak M, Schirmacher P, Ritz E. Calcification of coronary intima, and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2: 121-134, 2007.
17. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drüeke TB, Massy ZA. The antioxi-dant N-acetylcysteine prevents accelerated atherosclerosis in uremic apo-lipoprotein, and knockout mice. Kidney Int 67: 2288-2294, 2005.
18. Jian B, Narula N, Li QY, Mohler ER, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 75: 457-465, 2003.
19. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17, 2000.
20. Lamawansa MD, Wysocki SJ, House AK, Norman PE. Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries. Br J Surg 83: 1101-1103, 1996.
21. Levey AS, Coresh J, Balk, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and signification. Ann Inter Med 139: 137-147, 2003.
22. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1, 25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 68: 1500-1510, 2005.
23. Milliner DS, Zinsmeister AR, Liebermann E, Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38: 931-936, 1990.
24. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor, and the vitamin D analog suppresses the progression of renal insufficiency in uremic mice. J Am Soc Nephrol 18: 1796-1806, 2007.
25. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003-1011, 2003.
26. Parfitt AM, Massry SG, Winfield AC, DePalma JR, Gordon A. Disordered calcium, and phosphorus metabolism during maintenance hemodialysis. Correlation of clinical, roentgenographic and biochemical changes. Am J Med 51: 319-330, 1971.
27. Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J, Kim SW. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 77: 1076-1085, 2010.
28. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-F757, 2008.
29. Somjen D, Kohen F, Amir-Zaltsman Y, Knoll E, Stern N. Vitamin D analogs modulate the action of gonadal steroids in human vascular cells in vitro. Am J Hypertens 13: 396-403, 2000.
30. Somjen D, Kohen F, Gayer B, Knoll E, Limor R, Baz M, Sharon O, Posner GH, Stern N. The non-calcemic vitamin D analog modulates both nuclear and putative membranal estrogen receptors in cultured human vascular smooth muscle cells. J Steroid Biochem Mol Biol 89: 397-399, 2004.
31. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483-1490, 2003.
32. Tan X, Lin Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Neprhol 17: 3382-3393, 2006.
33. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003.
34. Wakasugi M, Noguchi T, Inoue M, Kazama Y, Tawata M, Kanemaru Y, Onaya T. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 42: 127-136, 1991.
35. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105: 15896-15901, 2008.